Vanda Pharmaceuticals (VNDA) Q2 2026 earnings review
Heavy Investments Crush Margins Despite Fanapt Growth
Vanda is executing an aggressive commercial and pipeline expansion, but the financial toll is severe. While Fanapt sales grew 23% YoY, total Q2 revenue declined 4% to $50.5M, optically worsened by a $7M delayed HETLIOZ shipment. The real story is the collapsing bottom line: operating expenses surged to $114.3M, driving a staggering $62.5M net loss. Cash dropped to $170M. Management insists this is a necessary peak-investment phase and expects expenses to moderate by late 2026, but the current burn rate paints a precarious picture for the balance sheet.
🐂 Bull Case
The bipolar I indication is clearly resonating. Prescriptions grew 31% YoY, proving the expanded 300-rep sales force is generating real volume growth ahead of the BYSANTI transition.
Vanda is rapidly evolving from a 3-product to a 5-6 product company. NEREUS launched in Q2, BYSANTI launches in H2, and Quimilza has a December PDUFA date.
🐻 Bear Case
The company burned $93.8M in H1 2026, leaving $170M on the balance sheet. Management claims cash will fund operations through 2027, which requires an immediate, massive deceleration in OpEx.
Generic competition continues to gut legacy revenues. Even accounting for a $7M delayed shipment, HETLIOZ sales are in structural decline, removing a previously reliable cash engine.
⚖️ Verdict: 🔴
Bearish. While the pipeline progress and Fanapt volume growth are genuine, the structural cash burn is too high. The company is in a race against its own balance sheet, relying on unprecedented expense reductions in 2027 to survive without dilution.
Key Themes
Cash Burn Runway Contradicts Guidance
Management states the $170M cash balance will fund operations 'through at least the end of 2027.' However, the company burned $32.3M in Q2 and $93.8M in H1 2026. This is a massive red flag: at the current run rate, the cash runway is less than 12 months. Hitting the 2027 guidance implies an abrupt reversing trend in spending that carries immense execution risk just as multiple products are launching.
Fanapt Bipolar Execution
Fanapt remains the stable growth engine, growing 23% YoY to $36.0M. Total prescriptions (TRx) accelerated by 31% and new-to-brand prescriptions (NBRx) grew 32% YoY. The aggressive investment in the 300-person sales force is yielding tangible market share gains in the bipolar space.
HETLIOZ Generic Erosion
HETLIOZ sales decelerated sharply, plunging 66% YoY to $5.6M. The company noted a $7.0M late shipment shifted to Q3, but even normalizing for this ($12.6M), the franchise is down 22% YoY. Generic erosion is permanently compressing Vanda's highest-margin legacy revenue stream.
NEREUS Direct-to-Consumer Innovation
NEREUS launched in Q2 via a novel direct-to-consumer platform (nereus.us), generating $1.0M in initial sales. Bypassing traditional pharmacy barriers with a cash-pay discount is an innovative approach to the 70 million patient motion sickness market. However, with personal promotion not starting until later in 2026, the scaling curve remains uncertain.
BYSANTI Franchise Extension
With the H2 2026 launch of BYSANTI (milsaperidone), Vanda executes its strategy to protect the Fanapt franchise ahead of a late-2027 loss of exclusivity. BYSANTI's data exclusivity lasts until 2031 (patents to 2044), and it is expected to offer significantly improved net pricing by resetting Medicaid rebates.
Surging R&D and SG&A Expenses
Operating margin compression is accelerating. Q2 R&D jumped 68% YoY to $37.0M, and SG&A rose 11% to $71.8M. The company is funding three Phase III clinical trials (including the GLP-1 side effect study) simultaneously while bearing commercial launch costs for NEREUS and BYSANTI. The strategic pivot to a diversified portfolio is extremely capital-intensive.
Other KPIs
Deteriorating rapidly. This compares to a net loss of -$27.2 million a year ago. H1 2026 net loss reached -$111.1 million, underscoring the severe near-term profitability sacrifice being made to establish the new commercial footprint.
Stable. Up 12% YoY from $7.1 million. The rollout of a dedicated 50-person specialty sales force is yielding modest, steady growth, though it remains a small contributor to the overall top line.
Guidance
Stable. The company reiterated its full-year guidance. At the midpoint ($265M), this implies a slight acceleration in H2 2026, as H1 generated $102.2M. Hitting this target will heavily rely on Fanapt momentum and the Q3 recognition of the $7M delayed HETLIOZ order.
Accelerating. With H1 Fanapt sales at $65.5M, hitting the $160M midpoint requires an acceleration to roughly $94.5M in H2, relying on continued bipolar market penetration and a successful initial BYSANTI launch.
Accelerating. The $1.0M print in Q2 means the product must scale dramatically in H2 to meet even the low end of this guidance. This places significant pressure on the upcoming 'personal promotion' campaign.
Key Questions
Bridging the Cash Runway
With $170M in cash and an H1 burn of $94M, the math to reach 'at least the end of 2027' requires massive expense cuts. Exactly which commercial or clinical programs will be halted or significantly reduced in 2027 to achieve this?
NEREUS Scaling Curve
NEREUS achieved $1M in Q2 via the DTC platform. What specific conversion metrics are you seeing on the website, and what gives you confidence it can scale to the $10M-$30M guidance range this year before personal promotion kicks in fully?
BYSANTI Cannibalization Strategy
As BYSANTI launches in H2, how will you actively shift the newly won bipolar Fanapt patients over to BYSANTI without losing them to competitor antipsychotics during the transition?